At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 269 enrolled
Drug / intervention
Bempedoic acid +2 moredrug
Likely dose
Bempedoic acid 180 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C
In Brief
A Phase 3 clinical trial evaluating Bempedoic acid, Ezetimibe, and 1 other intervention for Hypercholesterolemia and 2 related conditions. Completed, enrolled 269 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedDec 2016
Primary CompletionJan 2018
Study CompletionFeb 2018
TodayJul 2026
First PostedDec 22, 2016
Enrollment StartNov 29, 2016
Primary CompletionJan 11, 2018
Study CompletionFeb 12, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.5 years ago
Interventions
Bempedoic aciddrug
bempedoic acid 180 mg tablet
Ezetimibedrug
ezetimibe 10 mg tablet
Placeboother
matching placebo tablet